Rothschild Investment LLC lifted its position in shares of ARK Genomic Revolution ETF (BATS:ARKG – Free Report) by 15.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 15,150 shares of the company’s stock after acquiring an additional 2,000 shares during the period. Rothschild Investment LLC’s holdings in ARK Genomic Revolution ETF were worth $357,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors have also made changes to their positions in ARKG. Hemington Wealth Management grew its position in ARK Genomic Revolution ETF by 44.6% during the fourth quarter. Hemington Wealth Management now owns 1,310 shares of the company’s stock valued at $30,000 after buying an additional 404 shares during the period. Union Bancaire Privee UBP SA acquired a new stake in shares of ARK Genomic Revolution ETF during the 4th quarter valued at about $45,000. National Bank of Canada FI grew its position in shares of ARK Genomic Revolution ETF by 28.4% during the 3rd quarter. National Bank of Canada FI now owns 4,155 shares of the company’s stock valued at $106,000 after acquiring an additional 920 shares during the period. IHT Wealth Management LLC acquired a new stake in shares of ARK Genomic Revolution ETF during the 3rd quarter valued at about $203,000. Finally, Clientfirst Wealth Management LLC acquired a new stake in ARK Genomic Revolution ETF in the fourth quarter valued at approximately $228,000.
ARK Genomic Revolution ETF Trading Up 6.8 %
Shares of ARKG opened at $25.21 on Wednesday. The firm has a 50 day simple moving average of $25.88 and a 200 day simple moving average of $25.41.
ARK Genomic Revolution ETF Profile
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.
Featured Stories
- Five stocks we like better than ARK Genomic Revolution ETF
- ETF Screener: Uses and Step-by-Step Guide
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- What Investors Need to Know About Upcoming IPOs
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- How to Evaluate a Stock Before Buying
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Want to see what other hedge funds are holding ARKG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARK Genomic Revolution ETF (BATS:ARKG – Free Report).
Receive News & Ratings for ARK Genomic Revolution ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARK Genomic Revolution ETF and related companies with MarketBeat.com's FREE daily email newsletter.
